200 Inner Belt Road
Suite 400
Somerville, MA 02143
United States
617 229 6499
https://www.finchtherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Matthew P. Blischak J.D. | Chief Executive Officer | N/A | N/A | N/A |
Mr. Lance Thibault CPA | Chief Financial Officer | N/A | N/A | 1966 |
Mr. James S. Sigler MBA | Executive Vice President of CMC | N/A | N/A | 1961 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
El ISS Governance QualityScore de Finch Therapeutics Group, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.